Digitale Ulzera bei systemischer Sklerose: Diagnostik und Therapie

Schlüsselwörter

systemische Sklerose - digitale Ulzera - Therapie - Iloprost - Endothelin-Rezeptor-Antagonist - Bosentan

Keywords

systemic sclerosis - digital ulcers - therapy - iloprost - endothelin-receptor-antagonist - bosentan

• Literatur

• 1 Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008; 35: 1801-1808
• 2 Brückner C, Becker MO, Kroenck T et al. Effect of Sildenafil on digital ulcers in systemic sclerosis – analysis from a single centre pilot study. Ann Rheum Dis 2009; 60: 835-843
• 3 Christopeit M, Schendel M, Föll J et al. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008; 22: 1062-1604
• 4 Deutsches Netzwerk für systemische Sklerodermie (DNSS); Stand 8/2007; http://www.sklerodermie.info/dnsscontent/m1/k5/index.aspxx
• 5 Distler O, Gay S. Sklerodermie. Internist 2010; 51: 30-38
• 6 Fiori G, Galluccio F, Braschi F et al. Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis. Clin Exp Rheumatol 2009; 27: 51-54
• 7 Fries R, Shariat K, von Wilmowsky H et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005; 112: 2980-2985
• 8 Kawald A, Burmester GR, Huscher D et al. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol 2008; 35: 1830-1837
• 9 Korn JH, Mayes M, Matucci CerinicM et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 12; 3985-3993
• 10 Kowal-Bielecka O, Landewé R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-628
• 11 Kuhn A, Haust M, Ruland V et al. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 2010; 49: 1336-1345
• 12 Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70: 32-38
• 13 Milanetti F, Bucha J, Testori A et al. Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis. Curr Stem Cell Res Ther 2010; Oct 18. [Epub ahead of print]
• 14 Milburn PB, Singer JZ, Milburn MA. Treatment of scleroderma skin ulcers with a hydrocolloid membrane. J Am Acad Dermatol 1989; 21 (2 Pt 1) 200-204
• 15 Mouthon L, Mestre-Stanislas C, Bérezné A et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010; 69: 214-217
• 16 Müller-Ladner U. Akrale Ischämiesyndrome: vom Raynaud-Syndrom zur systemischen Sklerose. Bremen/London/Boston: UNI-MED Verlag AG; 2009
• 17 Ozgocmen S, Kaya A, Coskun BK. Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma). Clin Rheumatol 2006; 25: 378-379
• 18 Pope J, Fenlon D, Thompson A et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000; (02) CD000953
• 19 Rademaker M, Cooke ED, Almond NE et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989; 4: 561-564
• 20 Rosato E, Borghese F, Pisarri S et al. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol 2009; 28: 1379-1384
• 21 Scherer HU, Burmester GR, Riemekasten G. Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis. Ann Rheum Dis 2006; 65: 1245-1247
• 22 Scorza R, Caronni M, Mascagni B et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001; 19: 503-508
• 23 Sebastiani M, Manfredi A, Colaci M et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum 2009; 61: 688-694
• 24 Shenoy PD, Kumar S, Jha LK et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology Oxford 2010; 49: 2420-2428
• 25 Steen V, Denton CP, Pope JE et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009; 48 (Suppl. 03) iii19-24
• 26 Sunderkötter C, Riemekasten G. Raynaud-Phänomen in der Dermatologie. Teil 2: Therapie. Hautarzt 2006; 57: 927-938
• 27 Sunderkötter C, Herrgott I, Brückner C et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009; 160: 835-843
• 28 Wigley FM, Wise RA, Seibold JR et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120: 199-206
• 29 Wigley FM, Seibold JR, Wise RA et al. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19: 1407-1414
• 30 Yoon J, Giacopelli J, Granoff D et al. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane. J Am Podiatr Med Assoc 2002; 92: 350-354